6 prescription digital therapeutics story angles to explore
About Karen Blum Karen Blum is AHCJ’s core subject matter leader on overall health IT.
Therapeutics
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO),
Does Karyopharm Therapeutics (NASDAQ:KPTI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, ‘The biggest investment risk
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease